Beam Therapeutics Inc. (BEAM) vs Precigen, Inc. (PGEN)

Beam Therapeutics Inc. and Precigen, Inc. are both Biotechnology companies. Beam Therapeutics Inc. and Precigen, Inc. are of similar size ($2.8B and $2.6B). Precigen, Inc. grew revenue faster over the last twelve months: 1,875.1% against 158.9%. Beam Therapeutics Inc. has the higher net margin (−55.5% vs −392.8%) and the lower return on invested capital (−1,599.3% vs −24.9%). Across the 18 metrics below, Beam Therapeutics Inc. leads on 12 and Precigen, Inc. on 6.

Valuation

Metric BEAM PGEN Biotechnology median
P/E n/m n/m 7.88
P/S 16.23 32.27 11.47
P/B 2.37 63.47 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 9.48 32.93 10.73
Earnings yield (3.38%) (13.29%) (28.84%)
Free cash flow yield (14.72%) (4.17%) (23.03%)

Profitability

Metric BEAM PGEN Biotechnology median
Gross margin 100.00% 90.67% 65.16%
Operating margin (242.27%) (46.08%) 0.00%
Net margin (55.45%) (392.81%) 0.00%
Free cash flow margin (238.90%) (134.42%) 0.00%
Return on equity (8.18%) (9,907.46%) (57.72%)
Return on assets (6.23%) (247.40%) (49.22%)
Return on invested capital (1,599.30%) (24.87%) 0.00%

Growth

Metric BEAM PGEN Biotechnology median
Revenue growth (TTM) 158.88% 1,875.05% 5.64%
EPS growth (last fiscal year) 82.31% (191.49%) —
Revenue growth, 5-year CAGR 466.27% (21.26%) 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric BEAM PGEN Biotechnology median
Debt to equity 0.09 2.15 0.00
Current ratio 14.57 4.58 4.73
Net debt to EBITDA 3.30 0.04 0.96

Dividend

Metric BEAM PGEN Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric BEAM PGEN Biotechnology median
Market cap 2.55b 2.78b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack